EGFR and non-small cell lung carcinoma: This multicenter double-blind phase III trial demonstrated that addition of anlotinib to gefitinib significantly reduced the risk of progression in treatment-naïve EGFR-mutated, advanced NSCLC patients, conferring PFS benefits among multiple subgroups of NSCLC patients, especially those with brain metastasis and broadly active against NSCLC of diverse genomic profiles.